Multiple Myeloma Research Foundation (MMRF) Recognizes Outstanding Partners in Academia and Industry

Prestigious Awards Recognize Innovation, Acceleration, and Collaboration

NORWALK, Conn.--()--The Multiple Myeloma Research Foundation (MMRF) today announced that it has awarded its three top awards to leading research partners in advancing novel therapies and research for treatment of multiple myeloma. This year the MMRF recognizes the University of California, San Francisco (UCSF) with the MMRF Innovator Award, a team of researchers from Winship Cancer Institute at Emory University with the MMRF Accelerator Award, and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, with the MMRF Collaborator Award.

“The recipients of these prestigious MMRF Awards—UCSF, Emory, and Onyx—have each demonstrated extraordinary vision and a dedication to transforming multiple myeloma research and drug development to improve and extend the lives of patients,” said Walter M. Capone, Chief Operating Officer of the MMRF. “We are proud to have partnered with them for so many years and extend our sincere gratitude for their incredible and ongoing commitment on behalf of myeloma patients.”

MMRF Innovator Award

The MMRF Innovator Award recognizes Drs. Thomas Martin, Jeffrey Wolf and Anuj Mahindra at the Helen Diller Family Comprehensive Cancer Center at UCSF for their extraordinary commitment to innovation in driving new treatment options as a means to improve outcomes for multiple myeloma patients. UCSF was selected for its outstanding efforts to move forward the unique collaboration of Sanofi, UCSF and the MMRF on the development of the Sanofi anti-CD38 program as well as aggressive efforts to push forward innovative ISTs within the Multiple Myeloma Research Consortium (MMRC).

MMRF Accelerator Award

The MMRF Accelerator Award recognizes Drs. Sagar Lonial, Jonathan Kaufman, Ajay Nooka, Lawrence Boise and Leon Bernal-Mizrachi at Winship Cancer Institute of Emory University for their outstanding efforts and exceptional contributions to starting new clinical trials supported through the MMRC and rapidly enrolling patients in those trials. In 2013, Emory had the best overall performance of the 16 member institutions of the MMRC for both the number of MMRC trial starts and patients enrolled. Additionally, Dr. Lonial provided exceptional leadership of the MMRC Steering Committee, PRC and the MMRF CoMMpass℠ Study Steering Committee.

MMRF Collaborator Award

The MMRF Collaborator Award recognizes Onyx for its outstanding commitment to collaboration as a means to advance the research and development of more effective treatments for patients with multiple myeloma. Onyx has shown a deep commitment to the multiple myeloma community through its extensive clinical development program and by collaborating with the MMRC on 11 trials, as well as partnering with the MMRF on an extensive expanded access program and by joining as a member of the pre-competitive consortium to support the MMRF Personalized Medicine Initiative.

The MMRF would like to thank all of its research institution and industry partners throughout the MMRC as well as in the MMRF CoMMpass Study, MMGI and various grant award programs for their outstanding accomplishments in 2013 and very generous collaborative efforts.

About the Multiple Myeloma Research Foundation (MMRF)

The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)(3) non-profit organization by twin sisters Karen Andrews and Kathy Giusti, soon after Kathy's diagnosis with multiple myeloma. The mission of the MMRF is to relentlessly pursue innovative means that accelerate the development of next-generation multiple myeloma treatments to extend the lives of patients and lead to a cure. As the world's number-one private funder of multiple myeloma research, the MMRF has raised over $240 million since its inception and directs 90% of total budget to research and related programming. As a result, the MMRF has been awarded Charity Navigator’s coveted four-star rating for 11 consecutive years, the highest designation for outstanding fiscal responsibility and exceptional efficiency. For more information about the MMRF, please visit: www.themmrf.org.

About the Multiple Myeloma Research Consortium (MMRC)

The Multiple Myeloma Research Consortium (MMRC) is a 509(a)(3) non-profit organization that integrates leading academic institutions to accelerate drug development in multiple myeloma. It is led from MMRC offices in Norwalk, Conn., and comprises 16 member institutions: Barbara Ann Karmanos Cancer Institute, Baylor Charles A. Sammons Cancer Center at Dallas, City of Hope, Dana-Farber Cancer Institute, Emory University's Winship Cancer Institute, the John Theurer Cancer Center at Hackensack University Medical Center, Mayo Clinic, Mount Sinai School of Medicine, Ohio State University, Sarah Cannon Research Institute, University Health Network (Princess Margaret Hospital), University of California-San Francisco, University of Chicago, University of Michigan, Virginia Cancer Specialists, and Washington University in St. Louis. The MMRC is the only consortium to join academic institutions through membership agreements, customized IT systems, and an integrated tissue bank. For more information, please visit www.themmrc.org.

Contacts

Media:
MMRF
Anne Quinn Young, MPH
203-652-0212
QuinnYoungA@themmrf.org

Release Summary

The MMRF today announced that it has awarded its three top awards to leading research partners in advancing novel therapies and research for treatment of multiple myeloma to UCSF, Emory and Onyx.

Sharing

Contacts

Media:
MMRF
Anne Quinn Young, MPH
203-652-0212
QuinnYoungA@themmrf.org